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Heavy chain antibodyAbstract Placental growth factor (PlGF) is a member of the vascular endothelial growth factor
(VEGF) family. Unlike VEGF, PlGF is dispensable for normal cell development as well as playing
various roles in pathological angiogenesis which occurs in tissue ischemia, inﬂammation, and malig-
nancy. The PlGF-1 has been considered as a potential candidate for the diagnosis and targeting of
pathological angiogenesis. Camelidae serum contains an important fraction of functional antibod-
ies, called heavy-chain antibodies (HcAbs) that are naturally devoid of light chains. Camelid HcAbs
recognize their cognate antigens by a single variable-domain, referred to as VHH or Nanobody.
Here, we describe the expression and puriﬁcation of recombinant human PlGF-1 (rhPlGF-1).
This protein was subsequently used for the preparation of camel heavy chain polyclonal antibody
against rhPlGF-1.
Figure 1 (a) Schemati
36 R. Arezumand et al.The recombinant expression plasmid pET-26b-hPlGF-1 was introduced into Escherichia coli
BL21 cells to express the rhPlGF-1 protein. Puriﬁed rhPlGF-1 was used to immunize camel, the spe-
ciﬁc reactivity of HcAb was determined with ELISA and western blot. Western blot analysis indi-
cated that the antiserum speciﬁcally reacted to the recombinant protein. The rhPlGF-1 protein and
its antibody may be used for the development of detection assays needed for clinical research.
ª 2014 Production and hosting by Elsevier B.V. on behalf of King Saud University.1. Introduction
Angiogenesis is an essential process in fetal development, tis-
sue regeneration and remodeling in pathologic conditions such
as tumor invasion and metastasis (Folkman, 2007). Angiogen-
esis is a complex process which is stimulated by a variety of
angiogenic growth factors (Bikfalvi, 2012; Gordon et al.,
2010). The vascular endothelial growth factors (VEGFs) are
considered as key molecules in this process. The VEGF family
currently includes VEGF-A, -B, -C, -D, -E, -F and placental
growth factor (Roy et al., 2006). PlGF is a secreted protein
that shares substantial structural similarity with VEGF. Four
PlGF isoforms (i.e. PlGF-1–4) are produced by alternative
splicing of PlGF genes in human.
It has been shown that PlGF-1 can stimulate vessel
growth and maturation directly by affecting endothelial and
mural cells, and indirectly by recruiting pro-angiogenic cell
types, the recruitment and maturation of angiogenesis-
competent myeloid progenitor cells and activating macro-
phages to release angiogenic and lymphangiogenic molecules
(Selvaraj et al., 2003). In physiological condition the PlGF is
undetectable but in pathological conditions is mainly up
regulated. Therefore the blockade of the PlGF can lead to
the inhibition of neovascularization and tumor metastasis
(Fischer et al., 2008).
Camelidae serum contains an important fraction of func-
tional antibodies, called heavy-chain antibodies (HcAb) which
are naturally devoid of light chains. Therefore, the Camelid
HcAbs recognize their cognate antigens by a single variable-do-
main, referred to as VHH or Nanobody (Behdani et al., 2012;
Muyldermans et al., 2009). Nanobodies have several inherent,
advantageous properties such as strict monomeric behavior,
high afﬁnity, solubility and stability and remarkable expression
yield of recombinant VHH in bacteria or yeast. These character-
istics have made the VHH an attractive next-generation reagent
for immunoassays and therapeutic applications.
The aim of this study was the production of rhPlGF-1 and
preparation of camel heavy chain polyclonal antibody directed
against this protein.c expression cassette of pET26-h2. Materials and methods
2.1. Construction of pET-26b-hPlGF-1 plasmid
Escherichia coli B21 strain and pET-26b plasmid were pur-
chased from Iranian Gene Bank (Pasteur Institute of Iran,
Tehran, Iran).
The synthetic hPlGF-1 construct (BIOMATIK, Canada)
was composed of coding sequence of the human PlGF-1 in-
serted between NcoI and XhoI restriction sites of the pET-
26b plasmid (Fig. 1). This construct was transformed into
E. coli BL21 cells. The integrity of the ﬁnal construct (pET-
26b-hPlGF-1) and the transformation process were conﬁrmed
by restriction digestion and DNA sequencing.
2.2. Expression and puriﬁcation of rhPlGF-1
The protein expression was induced by the addition of 1 mM
isopropyl-D-thiogalactopyranoside (IPTG). After overnight
incubation at 37 C, the bacterial cells were pelleted and
homogenized by ultrasonication in analysis buffer (8 M urea,
20 mM Tris–HCl, 500 mM NaCl, 50 mM Imidazol, 0.5% tri-
ton X-100 and protease inhibitor). The bacterial cell lysate
was centrifuged at 8000g for 30 min. The supernatant was
loaded on a Ni–NTA column and washed with 4 M urea,
20 mM Tris–HCl, 500 mM NaCl, 60 mM Imidazol, and prote-
ase inhibitor. The bound proteins were eluted with 500 mM
Imidazole in PBS. The eluted protein was loaded on a gel ﬁl-
tration column (Sephadex 75- GE-Healthcare).
2.3. SDS–PAGE and western blotting analysis
Puriﬁed rhPlGF-1was determined on SDS–PAGE with 12%
resolving gel and 5% stacking gel. For western blotting the
separated protein was transferred onto nitrocellulose mem-
brane, and the membrane was blocked with 2% skimmed milk
in PBS for 2 h at room temperature (RT) and incubated with
1/3000 mouse anti-hPlGF-1(Cell Science) overnight at 4 C.PLGF-1, (b) The amino acid sequence of hPLGF-1.
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horseradish peroxidase (HRP)-conjugated anti-mouse IgG
overnight at 4 C. The immunoreactive bands were visualized
with developer solution containing 4-choloro-1-naftol. The
commercial human PlGF (Cell Science) was used as control. A
similar set up was used to determine the immunoreactivity and
speciﬁcity of the camel polyclonal antibody raised against the re-
combinant protein. Brieﬂy, the rhPlGF-1 protein on the mem-
brane was incubated with the 1/1000 dilution of puriﬁed camel
heavy-chain fraction overnight at 4 C. Themembrane was then
incubated with 1/16,000 rabbit anti-camel antibody for 1 h at
RT. Then, the membrane was incubated with 1:3000 HRP-con-
jugated anti-rabbit to reveal immuno reactive bands.
2.4. Preparation of polyclonal camel heavy chain antibody
against rhPlGF-1
An 8-month-old male camel Research and Production Com-
plex was kept at Pasteur Institute of Iran (Animal Sciences
Branch) under appropriate conditions. Blood serum samples
were collected before the injection of the antigen and stored
at 80 C.
The camel was immunized with six weekly subcutaneous
injections at neck. At each injection, 100 lg of rhPlGF-1 in
2 ml PBS was mixed with 2 ml Freund’s complete adjuvant for
the ﬁrst immunization, and with 2 ml of Freund’s incomplete
adjuvant for the following immunizations.
The serum samples were harvested at weeks 4 and 7. Heavy
chain antibodies were isolated according to the standard proto-
col (Hamers-Casterman et al., 1993). Brieﬂy, 5 ml of camel ser-
um was loaded on protein G Sepharose column (GE-
Healthcare) and was washed with 20 mM phosphate buffer
pH 7. IgG3 fraction was eluted with 0.15 M NaCl and 0.58%
acetic acid (pH 3.5) and IgG1 fraction was eluted with 0.1 M
Glycin–HCl (pH 2.7). For the isolation of IgG2 fraction, the
ﬂow through of the protein G Sepharose column was applied
onto protein A Sepharose column (GE-Healthcare). AfterFigure 2 Gel ﬁltration chromatography proﬁle of the Ni–NTA puriwashing with phosphate buffer, the absorbed fraction was
eluted with 0.15 M NaCl and 0.58% acetic acid (pH 4.5).
2.5. Functional assay
The reactivity of the puriﬁed camel heavy chain antibody with
recombinant rhPlGF-1 was examined by western blotting, as
described above and ELISA. For ELISA each well was coated
with 1 lg/ml of rhPlGF-1 and blocked with 2% skimmed milk.
The puriﬁed heavy chain polyclonal antibody was added to
wells at different dilutions starting from 1/200 to 1/50,000.
The bound antibody was detected using 1/16,000 dilution of
rabbit anti-camel antibody and 1/3000 dilution of HRP-conju-
gated anti-rabbit antibody.3. Results
3.1. Expression and characterization of rhPlGF-1
The integrity of the pET-26b-hPlGF-1 construct was shown by
double digestion with NcoI and XhoI restriction enzymes and
DNA sequencing. The rhPlGF-1was expressed as His-tag fu-
sions and puriﬁed by Ni–NTA afﬁnity chromatography and
gel ﬁltration. The gel ﬁltration result revealed that the recombi-
nant protein is monomeric (Fig. 2). The ﬁnal yield was 5 mg/lit.
The puriﬁcation process was conﬁrmed using SDS–PAGE. The
rhPlGF-1 is present as a single band about 15 kDa (Fig. 3a). The
western blot analysis was done with commercial anti-PlGF anti-
body (Cell Science) and revealed that the puriﬁed recombinant
protein was successfully transferred onto the nitrocellulose-
membrane and had migrated at estimated size (Fig. 3b).
3.2. The camel HcAb speciﬁc to rhPlGF-1
The camel was immunized weekly for six times with rhPlGF-1.
The immune response was followed by ELISA analysis withﬁed rhPLGF-1, loaded onto a superdex 75 column in PBS buffer.
Figure 3 Expression and characterization of the rhPlGF-1. (a) SDS–PAGE. Lane1, before induction; Lane2, Induced with 1 mM IPTG;
Lane3, Puriﬁed protein. (b) Western Blotting. Lane 1, puriﬁed rhPlGF-1 protein; Lane 2, commercial human PlGF-1. Lane M: protein
molecular weight marker.
Figure 4 The SDS–PAGE pattern of puriﬁed camel antibodies
in reduced condition. Lane 1, the conventional camel antibody
(IgG1) with light and heavy chain. Lane 2, 3, the heavy chain
antibodies (IgG2, 3 respectively).
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Figure 5 Sensitivity analysis of HcAbs by ELISA. The camelid
HcAbs antibody at different dilutions (1:200 to 1:50,000) reacted
with the recombinant rhPLGF protein.
38 R. Arezumand et al.puriﬁed HcAb. The standard protocol was used for HcAbs
puriﬁcation. As shown in Fig. 4, we can separate the HcAbs
from conventional antibodies.
During the course of immune response, the puriﬁed HcAbs
were diluted at 1/200 to 1/50,000 and tested for reactivity. Asshown in Fig. 5, speciﬁc antibody titers raised rapidly after the
fourth injection.
Western blot analysis was performed to determine the spec-
iﬁcity of the heavy-chain antibodies (Fig. 6), which revealed
that the rhPlGF-1 could be recognized by the heavy-chain
polyclonal antibody. These results indicated that the heavy-
chain polyclonal antibody has high speciﬁcity for the
rhPlGF-1 protein.
4. Discussion
Development of antibodies speciﬁc to biomarkers has mainly
focused on mouse antibodies. Alternatively, recent studies on
camelid immunoglobulins provide a compelling rationale for
Figure 6 Determination of speciﬁcity by western blot analysis in
non-reducing condition with Heavy-chain polyclonal antibody.
Lane 1, puriﬁed rhPlGF-1, Lane 2, commercial human PlGF-1,
M, protein molecular weight marker.
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tion of the tumor-associated markers). In this study, we de-
scribed the expression and puriﬁcation of rhPlGF-1 and its
application for camelid polyclonal antibody preparation. The
pET26b-hPlGF-1 construct expressed more than 5 mg/lit of
the desired protein and the puriﬁed product was successfully
used for camel immunization. The camel heavy chain poly-
clonal anti-PlGF-1 detected the rhPlGF-1 protein as well as
commercial rhPlGF-1in an ELISA assay.
Interestingly, over 50% of camelid immunoglobulin lack
light chain and the 15 kDa antigen binding domain of the hea-
vy chain antibody (VHH, obtained by protease cleavage) is
considerably smaller than papain cleaved Fab fragments
(60 kDa) of conventional IgG (Rahbarizadeh et al., 2011).
Camelid heavy chain IgG is also less immunogenic than most
mammalian IgG (Cortez-Retamozo et al., 2002) indicating
that intravenous administration of camelid antibody is less
likely to induce the anti-antibody and anaphylactic adverse
reactions (Lalloo and Theakston, 2003). Unlike conventional
IgG, in some reports, the antigen-binding capabilities of cam-
elid HcAbs and derived VHH are not affected by exposure to
high temperatures. (Graef et al., 2011; Ladenson et al., 2006;
van der Linden et al., 2000).
PlGF-1 is a tumor associated marker which has several
important roles including role in pathological conditions in tu-
mor angiogenesis, as an important bio marker in patients with
coronary artery disease, facilitates cardiac healing after myo-
cardial hypoxia/ischemia, and improves wound healing in dia-
betes (Ribatti, 2011). Therefore, PlGF protein level detection is
a useful tool for disease progress determination.
Our results showed that the anti-PlGF-1 polyclonal HcAb
can be used to detect the PlGF-1 and for the development of
diagnostic assays. Furthermore, the ﬁndings reported here
may pave the way for the development of a speciﬁc Nanobody
against PlGF for in vivo studies and anticancer applications.Acknowledgments
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